<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014403</url>
  </required_header>
  <id_info>
    <org_study_id>082009-026</org_study_id>
    <nct_id>NCT01014403</nct_id>
  </id_info>
  <brief_title>Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)</brief_title>
  <acronym>DEEP</acronym>
  <official_title>The Delayed vs Early Enoxaparin Prophylaxis (DEEP) Study After Traumatic Brain Injury: A Randomized, Double-Blinded, Placebo Controlled Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brain injured patients are at high risk for forming blood clots in the legs and lungs. For&#xD;
      non-brain injured trauma patients, we decrease the chances of these blood clots forming by&#xD;
      placing the patients on a low dose of the blood thinner enoxaparin. Starting patients with a&#xD;
      brain injury on the blood thinner is problematic, however, as this can theoretically cause&#xD;
      the brain injury to worsen. Trauma surgeons wait a variable period of time before starting&#xD;
      this blood thinner because waiting too long can result in the formation of these blood clots&#xD;
      in the legs and lungs. Previous research has shown that some brain injuries which are of&#xD;
      lower severity can have enoxaparin started at 24 hours after injury if the brain injury is&#xD;
      stable on a repeated computed tomography (CT) scan of the head. This is a pilot study&#xD;
      designed to look at the rates of worsening of brain injury if the low dose blood thinner is&#xD;
      started at 24 versus 96 hours post-injury.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to conduct a placebo-controlled non-inferiority pilot study to evaluate the rate&#xD;
      of worsening of intracranial injury patterns after initiation of enoxaparin in TBI patients.&#xD;
      Patient enrollment will occur at ETMC, blinded re-reading of CTs will occur at PMH, and&#xD;
      administrative/analytical support will occur at UTSW. The study design will be a&#xD;
      double-blind, randomized controlled trial in the ETMC Surgical Intensive Care Unit (SICU)&#xD;
      consisting of 40 patients per arm. The decision for 80 patients was resource-based, as this&#xD;
      is a pilot study. Further, we anticipate the need to contact 3 patients in order to obtain 1&#xD;
      successful recruitment.&#xD;
&#xD;
      Each arm will consist of low-risk TBI patients (defined as patients with a subdural or&#xD;
      epidural hematoma &lt; 8mm, intraparenchymal contusion &lt; 2 cm, and/or single contusion per lobe)&#xD;
      who have had a CT scan of the head without contrast at 24 hours post-injury which documents a&#xD;
      stable injury pattern. The severity of neurologic deficit will have no bearing on their&#xD;
      suitability for participation, and will not be considered in inclusion/exclusion criteria.&#xD;
      After documentation of a stable intracranial injury pattern at this time interval, patients&#xD;
      will be randomized to receive either enoxaparin 30 mg SQ every 12 hours or placebo with each&#xD;
      regimen being initiated at 24 hours post-injury. A follow-up CT scan of the brain without&#xD;
      contrast will be obtained on all patients 48 hours post-injury (and 24 hours after the&#xD;
      initiation of enoxaparin/placebo). An additional CT scan of the brain without contrast will&#xD;
      be obtained on any patient who experiences an abrupt change in neurologic exam at any time&#xD;
      between the initiation of enoxaparin/placebo and the end of the study's interventional period&#xD;
      at 96 hours post-injury (this time frame was chosen as it is the earliest time point at which&#xD;
      there is universal agreement among both of our group's practitioners that enoxaparin use is&#xD;
      safe from the risks of TBI expansion). Any patient with a worsened CT scan will have their&#xD;
      investigational treatment discontinued at that time. At 96 hours post-injury, the&#xD;
      interventional portion of the study will end, data collection for the primary endpoint will&#xD;
      cease, and all patients will be placed on enoxaparin for the remainder of their hospital stay&#xD;
      as per local standards of care. Patient participation in the study will last from the time of&#xD;
      injury to 96 hours post-injury for the interventional part of the study, and from 96 hours&#xD;
      post-injury until discharge from ETMC for the observational portion. While this latter time&#xD;
      frame is obviously extremely variable, it averages approximately one to two weeks. During&#xD;
      both the interventional and observational time periods, patients will have Duplex&#xD;
      ultrasonography of the lower extremities performed for an edematous extremity, CT-angiography&#xD;
      of the chest for unexplained hypoxia or tachycardia, and ventilation-perfusion scanning for&#xD;
      suspicion of PE in the presence of a contraindication to IV contrast.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Worsening TBI Hemorrhage</measure>
    <time_frame>24 hours after the start of treatment/48 hours after the time of injury</time_frame>
    <description>Worsening of TBI hemorrhage pattern on any scheduled or PRN CT scans after the initiation of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extracranial Hemorrhagic Complications</measure>
    <time_frame>prior to discharge</time_frame>
    <description>percentage of participants that have extracranial hemorrhagic complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)</measure>
    <time_frame>prior to discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>enoxaparin 30 mg SQ q12 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enoxaparin started at 24 hours post-injury and continued until 96 hours post-injury.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vehicle administered sq q 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enoxaparin</intervention_name>
    <description>Enoxaparin 30 mg sq q 12 hours</description>
    <arm_group_label>enoxaparin 30 mg SQ q12 hours</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>vehicle</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Male and female patients admitted to the ETMC SICU with TBI who speak English or&#xD;
        Spanish.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Epidural or subdural hematoma &gt; 8mm.&#xD;
&#xD;
          2. Intraparenchymal contusion &gt;2 cm&#xD;
&#xD;
          3. Multiple contusions w/in one lobe&#xD;
&#xD;
          4. Subarachnoid hemorrhage in basilar or supracellar cistern and positive CTA&#xD;
&#xD;
          5. Increased TBI on 24 hr post-injury CT&#xD;
&#xD;
          6. Spinal canal hematoma&#xD;
&#xD;
          7. Nonoperative mgmt of American Association for the Surgery of Trauma (AAST) Grade IV or&#xD;
             higher organ injury&#xD;
&#xD;
          8. Gastrointestinal hemorrhage&#xD;
&#xD;
          9. Ongoing bleeding from a pelvic fracture&#xD;
&#xD;
         10. Anticipated open reduction of long bone or pelvic fracture within study period.&#xD;
&#xD;
         11. Intracranial pressure (ICP) &gt;20 mmHg&#xD;
&#xD;
         12. Coagulopathy consisting of International Normalized Ratio (INR)&gt;1.5 or platelet count&#xD;
             &lt;50,000&#xD;
&#xD;
         13. Expect brain death/discharge in 48 hrs&#xD;
&#xD;
         14. Pre-existing dialysis dependence&#xD;
&#xD;
         15. Documented DVT at time of admission&#xD;
&#xD;
         16. Prisoners&#xD;
&#xD;
         17. Pregnancy&#xD;
&#xD;
         18. Age &lt;18 years&#xD;
&#xD;
         19. Terminally ill patients&#xD;
&#xD;
         20. Anticoagulant use at time of injury&#xD;
&#xD;
         21. Inability to gain consent from patient or legal next-of-kin in instance of TBI,&#xD;
             intoxication, or psychiatric diagnoses&#xD;
&#xD;
         22. Documented history of heparin allergy&#xD;
&#xD;
         23. Initial head CT &gt;6 hours post-injury&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herb A Phelan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT-Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Texas Medical Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 13, 2009</study_first_submitted>
  <study_first_submitted_qc>November 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2009</study_first_posted>
  <results_first_submitted>December 4, 2018</results_first_submitted>
  <results_first_submitted_qc>December 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 13, 2021</results_first_posted>
  <last_update_submitted>December 19, 2020</last_update_submitted>
  <last_update_submitted_qc>December 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>venous thromboembolism</keyword>
  <keyword>enoxaparin</keyword>
  <keyword>traumatic brain injury</keyword>
  <keyword>Venous thromboembolism prophylaxis traumatic brain injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Enoxaparin 30 mg SQ q12 Hours</title>
          <description>Enoxaparin started at 24 hours post-injury and continued until 96 hours post-injury.&#xD;
enoxaparin: Enoxaparin 30 mg sq q 12 hours</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>vehicle administered sq q 12 hours&#xD;
placebo: vehicle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enoxaparin 30 mg SQ q12 Hours</title>
          <description>Enoxaparin started at 24 hours post-injury and continued until 96 hours post-injury.&#xD;
enoxaparin: Enoxaparin 30 mg sq q 12 hours</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>vehicle administered sq q 12 hours&#xD;
placebo: vehicle</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="19"/>
                    <measurement group_id="B2" value="42" spread="17"/>
                    <measurement group_id="B3" value="41" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Worsening TBI Hemorrhage</title>
        <description>Worsening of TBI hemorrhage pattern on any scheduled or PRN CT scans after the initiation of treatment</description>
        <time_frame>24 hours after the start of treatment/48 hours after the time of injury</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enoxaparin 30 mg SQ q12 Hours</title>
            <description>Enoxaparin started at 24 hours post-injury and continued until 96 hours post-injury.&#xD;
enoxaparin: Enoxaparin 30 mg sq q 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>vehicle administered sq q 12 hours&#xD;
placebo: vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Worsening TBI Hemorrhage</title>
          <description>Worsening of TBI hemorrhage pattern on any scheduled or PRN CT scans after the initiation of treatment</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="0.7" upper_limit="19.7"/>
                    <measurement group_id="O2" value="3.6" lower_limit="0.1" upper_limit="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extracranial Hemorrhagic Complications</title>
        <description>percentage of participants that have extracranial hemorrhagic complications</description>
        <time_frame>prior to discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enoxaparin 30 mg SQ q12 Hours</title>
            <description>Enoxaparin started at 24 hours post-injury and continued until 96 hours post-injury.&#xD;
enoxaparin: Enoxaparin 30 mg sq q 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>vehicle administered sq q 12 hours&#xD;
placebo: vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Extracranial Hemorrhagic Complications</title>
          <description>percentage of participants that have extracranial hemorrhagic complications</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)</title>
        <time_frame>prior to discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enoxaparin 30 mg SQ q12 Hours</title>
            <description>Enoxaparin started at 24 hours post-injury and continued until 96 hours post-injury.&#xD;
enoxaparin: Enoxaparin 30 mg sq q 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>vehicle administered sq q 12 hours&#xD;
placebo: vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Enoxaparin 30 mg SQ q12 Hours</title>
          <description>Enoxaparin started at 24 hours post-injury and continued until 96 hours post-injury.&#xD;
enoxaparin: Enoxaparin 30 mg sq q 12 hours</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>vehicle administered sq q 12 hours&#xD;
placebo: vehicle</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Herb Phelan</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>214-648-6841</phone>
      <email>herb.phelan@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

